#United States #San Diego #Class Action #deramiocel #Capricor Therapeutics

Capricor Therapeutics Investors: Lead the Class Action Lawsuit

The law firm Robbins Geller Rudman & Dowd LLP has announced a crucial opportunity for investors of Capricor Therapeutics (NASDAQ: CAPR) who acquired shares between December 17, 2025, and July 26, 2026. This announcement signals a deadline on September 28, 2026, for those affected by substantial losses to apply as lead plaintiffs in a class action lawsuit against the company.

Legal Background

The lawsuit, known as Nkamga v. Capricor Therapeutics, Inc., has potentially significant implications for those involved. Allegations point towards Capricor and some of its top executives for violations of the Securities Exchange Act of 1934. If you purchased shares during the specified class period and experienced financial losses, you may be entitled to lead this class action lawsuit.

Capricor Therapeutics is focused on developing innovative therapies such as Deramiocel, a cell therapy designed to treat complications of Duchenne muscular dystrophy, a rare genetic disorder marked by severe muscle degradation. However, various claims allege that during the class period, Capricor misled investors regarding significant changes in its statistical analysis plan related to clinical trials of Deramiocel, failing to disclose crucial information regarding its approval process by the FDA.

Allegations Explained

Reports indicate that the company's alleged failures included:

1. Capricor's adjustments to the analytical framework used to review its clinical data were neither declared nor agreed upon by the FDA prior to the application submission.
2. This lack of communication heightened concerns over the effectiveness of Deramiocel, which subsequently jeopardized its regulatory approval for treating Duchenne muscular dystrophy.

In recent developments on July 27, 2026, the FDA released briefing materials ahead of an advisory committee meeting, revealing Capricor's problematic adjustments to the pre-defined analysis plan. According to court documents, the FDA expressed serious doubts about the validity of these changes, indicating possible risks that could endanger the market standing of Capricor's product.

Following this news, Capricor's share price experienced dramatic declines—64% post-disclosure—highlighting the gravity of the situation for investors. Further discussions during the advisory committee led to a non-binding vote indicating insufficient evidence supporting Deramiocel's efficacy, which caused an additional 36% drop in the stock's value soon after.

Opportunity to Act

The Private Securities Litigation Reform Act of 1995 allows any investor who engaged with Capricor securities during this period to apply to act as lead plaintiff. This role is important as it shapes the direction of the lawsuit, and plaintiffs can select law firms of their choice to handle their case.

Investors do not have to be lead plaintiffs to benefit from any potential recoveries, and interested parties can learn more about this opportunity on Robbins Geller's website.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP stands as a prominent law firm recognized for representing investors facing securities fraud and shareholder rights violations. The firm boasts an impressive recovery record, having secured over $916 million in investor losses in 2025 alone and ranking first in multiple litigation categories over the past few years.

As the situation with Capricor Therapeutics evolves, investors are encouraged to take this opportunity seriously and consider their involvement in the class action. Timely action could lead to recovering a fraction of the financial losses incurred during this tumultuous period in the biotech sector.